Genomic Health (GHDX) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
- Qualcomm shares fall on Intel warning and legal concerns
- Marvell Technology shares drop on Lumentum deal concerns
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Oracle shares drop on AI spending concerns and Microsoft criticism
- SpaceX stock drops on launch setback and sector selloff
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Genomic Health Announces Second Quarter 2015 Financial Results and Reports Record International and Prostate Cancer Tests Delivered
August 4, 2015 4:07 PM EDTREDWOOD CITY, Calif., Aug. 4, 2015 /PRNewswire/ --Â Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2015.
Revenue was $70.6 million in the second quarter of 2015 compared with $70.5 million for the second quarter of 2014.
International revenue was $9.9 million in the second quarter of 2015, down from $11.9 million in the second quarter of 2014, and represented 14 percent of revenue in the quarter. Although international test volume reached record levels, revenue was impacted negatively from foreign exchange (FX) rate differences due to the stronger dollar and by... More



